Levetiracetam Mechanisms of Action: From Molecules to Systems
Open accessThe DOI matches its Crossref record; 302 of the 303 references it cites were found in a registry or an index.
Abstract
Epilepsy is a chronic disease that affects millions of people worldwide. Antiepileptic drugs (AEDs) are used to control seizures. Even though parts of their mechanisms of action are known, there are still components that need to be studied. Therefore, the search for novel drugs, new molecular targets, and a better understanding of the mechanisms of action of existing drugs is still crucial. Levetiracetam (LEV) is an AED that has been shown to be effective in seizure control and is well-tolerable, with a novel mechanism of action through an interaction with the synaptic vesicle protein 2A (SV2A). Moreover, LEV has other molecular targets that involve calcium homeostasis, the GABAergic system, and AMPA receptors among others, that might be integrated into a single mechanism of action that could explain the antiepileptogenic, anti-inflammatory, neuroprotective, and antioxidant properties of LEV. This puts it as a possible multitarget drug with clinical applications other than for epilepsy. According to the above, the objective of this work was to carry out a comprehensive and integrative review of LEV in relation to its clinical uses, structural properties, therapeutical targets, and different molecular, genetic, and systemic action mechanisms in order to consider LEV as a candidate for drug repurposing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Across models of stress, epilepsy, and neurodegeneration, modulation of SV2A preserves synaptic structure and maintains transmission after plasticity induction [173,175,199].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Functionally, SV2A modulation limits the slide from induced plasticity to maladaptive remodeling and relapse-like behavior [175,199,205].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“After ketamine or other plasticity-promoting interventions, preserving vesicle cycling and maintaining a competent readily releasable pool appear crucial for sustaining gains; animal studies link antidepressant durability to synaptic integrity supported by SV2A pathways and complementary signaling through ERK and calcium channels [199,201,205].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Levetiracetam restores vesicle fusion fidelity, rescues basal transmission, and normalizes synaptic protein composition, effects that depend on direct SV2A engagement and extend to hippocampal volume and plasticity recovery [173,175,199].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In stress-sensitized and developmental perturbation paradigms, levetiracetam reverses anxiety-like, cognitive, and social deficits while rebalancing hippocampal and mesolimbic activity, consistent with network-level stabilization of prefrontal–hippocampal circuits [175,199].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [199]
Experimental — accuracy not yet measured
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ILAE official report: a practical clinical definition of epilepsy
Fisher, R. S., Acevedo, C., Arzimanoglou, A., Bogacz, A., Cross, J. H., Elger, C. E., Engel, J., Forsgren, L., French, J. A., Glynn, M., et al. (2014) · Epilepsia · doi:10.1111/epi.12550 · Cited by 6,108 · cited 1×
“It is a chronic neurological disorder characterized by the presence of spontaneous and recurrent seizures caused by hyperactivity and the abnormal synchronization of neurons [2] that results in neuronal damage, inflammation, and the generation of reactive oxygen species”
BackgroundFisher, R. S., Cross, J. H., French, J. A., Higurashi, N., Hirsch, E., Jansen, F. E., Lagae, L., Moshé, S. L., Peltola, J., Roulet Perez, E., et al. (2017) · Epilepsia · doi:10.1111/epi.13670 · Cited by 3,483 · cited 1×
“According to the International League Against Epilepsy (ILAE), epileptic seizures are classified as focal-onset, generalized-onset, and unknown-onset seizures (previously known as partial and generalized seizures) [3].”
BackgroundTrinka, E., Cock, H., Hesdorffer, D., Rossetti, A. O., Scheffer, I. E., Shinnar, S., Shorvon, S., & Lowenstein, D. H. (2015) · Epilepsia · doi:10.1111/epi.13121 · Cited by 2,494 · cited 1×
“Status epilepticus (SE) is an emergency condition characterized by long-term seizures in which seizures lasting more than 30 min can be fatal [43]; benzodiazepines have been used as a first-line treatment for this condition.”
BackgroundThe role of inflammation in epilepsy
Vezzani, A., French, J., Bartfai, T., & Baram, T. Z. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.178 · Cited by 1,876
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · cited 2×
“Currently, there is no doubt that LEV binds in a saturable, reversible, and stereospecific manner to SV2A in both rat and human brains; this is also true for its structural analogs [9,103].”
BackgroundGlia and epilepsy: excitability and inflammation
Devinsky, O., Vezzani, A., Najjar, S., De Lanerolle, N. C., & Rogawski, M. A. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2012.11.008 · Cited by 867
Buckley, K., & Kelly, R. B. (1985) · The Journal of cell biology · doi:10.1083/jcb.100.4.1284 · Cited by 712
Pitkänen, A., & Sutula, T. P. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00073-x · Cited by 637 · cited 1×
“Antiepileptic drugs (AEDs; also named antiseizure drugs) efficiently control seizures, but only in about 2/3 of people with epilepsy [4]; moreover, during the last few years it has become clear that the current way of treating epilepsy with AEDs that only controls seizures is insufficient, since it does not cover the…”
BackgroundLevetiracetam for partial seizures: Results of a double-blind, randomized clinical trial
Cereghino, J. J., Biton, V., Abou-Khalil, B., Dreifuss, F., Gauer, L. J., Leppik, I., & the United States Levetiracetam Study Group (2000) · Neurology · doi:10.1212/wnl.55.2.236 · Cited by 524
Pharmacokinetic profile of levetiracetam
Patsalos, P. N. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00052-2 · Cited by 519
Infections, inflammation and epilepsy
Vezzani, A., Fujinami, R. S., White, H. S., Preux, P.-M., Blümcke, I., Sander, J. W., & Löscher, W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1481-5 · Cited by 518
Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy
Klitgaard, H., Matagne, A., Gobert, J., & Wülfert, E. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00410-5 · Cited by 506 · cited 2×
“This probably explains the lack of anticonvulsant activity against acute seizures [198] compared with their potent anticonvulsant action in chronic models, as well as its unique tolerability and safety [202].”
BackgroundMechanisms of action of currently used antiseizure drugs
Sills, G. J., & Rogawski, M. A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107966 · Cited by 489 · cited 1×
“Therefore, LEV can affect gene expression [122,185,186].”
Shorvon, S. D., Löwenthal, A., Janz, D., Bielen, E., Loiseau, P., & for the European Levetiracetam Study Group (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb00323.x · Cited by 451 · cited 1×
“4% of patients in the placebo group [34].”
BackgroundDifferential expression of synaptic vesicle protein 2 (SV2) isoforms
Bajjalieh, S., Frantz, G., Weimann, J., McConnell, S., & Scheller, R. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-09-05223.1994 · Cited by 440
Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)
Crowder, K. M., Gunther, J. M., Jones, T. A., Hale, B. D., Zhang, H. Z., Peterson, M. R., Scheller, R. H., Chavkin, C., & Bajjalieh, S. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15268 · Cited by 415 · cited 3×
“SV2A KO mice showed severe seizures and died within 3 weeks [112].”
BackgroundLöscher, W., & Brandt, C. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003046 · Cited by 414
Ben‐Menachem, E., & Falter, U. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb04605.x · Cited by 409 · cited 1×
“4%) even remained seizure-free, which suggests that the conversion to LEV monotherapy (1500 mg twice daily) is effective and well tolerated in patients with refractory focal-onset seizures who responded to 3000 mg/day LEV as an add-on therapy [35].”
BackgroundPsychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy
Chen, B., Choi, H., Hirsch, L. J., Katz, A., Legge, A., Buchsbaum, R., & Detyniecki, K. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2017.08.039 · Cited by 399
Christensen, J., Pedersen, M. G., Pedersen, C. B., Sidenius, P., Olsen, J., & Vestergaard, M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60214-2 · Cited by 379
SV2A and SV2B Function as Redundant Ca2+ Regulators in Neurotransmitter Release
Janz, R., Goda, Y., Geppert, M., Missler, M., & Südhof, T. C. (1999) · Neuron · doi:10.1016/s0896-6273(00)81046-6 · Cited by 367 · cited 2×
“Since the absence of SV2A presented a normal number of vesicles docked at the active zone in presynaptic terminal [113,115] and the mechanism of exocytosis itself was not affected (no changes were observed in any SV2A KO and SV2A/SV2B DKO hippocampal neurons when examining miniature postsynaptic currents) [109,112,113…”
BackgroundLöscher, W., Hönack, D., & Rundfeldt, C. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37251-9 · Cited by 343 · cited 2×
“[218] Rat amygdala kindling model 13, 27 or 54 mg/kg i.”
BackgroundSelective Blockade of N‐Type Calcium Channels by Levetiracetam
Lukyanetz, E. A., Shkryl, V. M., & Kostyuk, P. G. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.24501.x · Cited by 338
Rigo, J., Hans, G., Nguyen, L., Rocher, V, Belachew, S., Malgrange, B., Leprince, P., Moonen, G., Selak, I., Matagne, A., et al. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704766 · Cited by 336 · cited 6×
“Another action of LEV in the GABAergic system involves the ability to reverse the inhibitory effects of the negative allosteric modulators β-carbolines and zinc on both GABAA and glycine receptors, the two main ionotropic inhibitory receptor systems in the brain [145].”
BackgroundMethodInfluentialEpilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review
Brodie, M. J., Besag, F., Ettinger, A. B., Mula, M., Gobbi, G., Comai, S., Aldenkamp, A. P., & Steinhoff, B. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012021 · Cited by 288 · cited 1×
“Aggressive behavior in epilepsy has been the subject of many misconceptions and controversies, however, it can be defined as “a social behavior that is aimed at eliciting discomfort, pain, or physical damage, to oneself, to another person, or to things or at defending oneself against a threat” [304,305].”
BackgroundMalykh, A. G., & Sadaie, M. R. (2010) · Drugs · doi:10.2165/11319230-000000000-00000 · Cited by 270
Hoffmann, A., Kann, O., Ohlemeyer, C., Hanisch, U.-K., & Kettenmann, H. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-11-04410.2003 · Cited by 263 · cited 2×
“chemokines from microglia activated responsible for neuroinflammation [300], suggesting that certain Ca2+ channels in microglia might be potent targets of LEV (Figure 7).”
BackgroundSV2, a Brain Synaptic Vesicle Protein Homologous to Bacterial Transporters
Bajjalieh, S. M., Peterson, K., Shinghal, R., & Scheller, R. H. (1992) · Science · doi:10.1126/science.1519064 · Cited by 256 · cited 2×
“placed SV2 proteins as the primary candidates [102].”
BackgroundNoyer, M., Gillard, M., Matagne, A., Hénichart, J.-P., & Wülfert, E. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00436-o · Cited by 255 · cited 1×
“LEV differs from classical AEDs since it does not share affinity with targets of other AEDs such as valproic acid, phenobarbital or benzodiazepines and does not work by the three classic routes of AEDs: sodium channel modulation, low-voltage-activated (T-type) calcium channel modulation and a direct GABAfacilitation […”
BackgroundGillard, M., Fuks, B., Leclercq, K., & Matagne, A. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.04.064 · Cited by 253 · cited 1×
“Currently, there is no doubt that LEV binds in a saturable, reversible, and stereospecific manner to SV2A in both rat and human brains; this is also true for its structural analogs [9,103].”
BackgroundLevetiracetam in the treatment of epilepsy
Abou-Khalil, B. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s2937 · Cited by 232
Kenda, B. M., Matagne, A. C., Talaga, P. E., Pasau, P. M., Differding, E., Lallemand, B. I., Frycia, A. M., Moureau, F. G., Klitgaard, H. V., Gillard, M. R., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030913e · Cited by 226 · cited 3×
“These molecular modifications were correlated to the fact that the bioactive conformation would form intramolecular hydrogen bonds between the 2-oxopyrrolidine and the carboxamide group, as well as to the lesser manifestation of severe toxic effects [16] (Figure 1B).”
BackgroundNiespodziany, I., Klitgaard, H., & Margineanu, D. G. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01884-5 · Cited by 220 · cited 1×
“The administration of LEV (32 μM) in CA1 of rat hippocampal slices decreased significantly the neuronal HVA Ca2+ currents [135].”
BackgroundSV2 modulates the size of the readily releasable pool of secretory vesicles
Xu, T., & Bajjalieh, S. M. (2001) · Nature Cell Biology · doi:10.1038/35087000 · Cited by 212 · cited 2×
“In addition, brain tissue from SV2A KO contained a smaller proportion of the syntaxin protein, consistent with the interpretation that the loss of SV2A affects the formation of the complex of soluble NSF attachment proteins receptor (SNARE; [113,115].”
BackgroundResultucb L059, a novel anti-convulsant drug: pharmacological profile in animais
Gower, A. J., Noyer, M., Verloes, R., Gobert, J., & Wülfert, E. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90855-x · Cited by 212 · cited 1×
“LEV is the S-enantiomer of the ethyl analog of piracetam [88] (Figure 1A).”
BackgroundSynaptic vesicle protein 2 enhances release probability at quiescent synapses
Custer, K. L., Austin, N. S., Sullivan, J. M., & Bajjalieh, S. M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2699-05.2006 · Cited by 211 · cited 2×
“In addition, brain tissue from SV2A KO contained a smaller proportion of the syntaxin protein, consistent with the interpretation that the loss of SV2A affects the formation of the complex of soluble NSF attachment proteins receptor (SNARE; [113,115].”
BackgroundResultGower, A. T., Hirsch, E., Boehrer, A., Noyer, M., & Marescaux, C. (1995) · Epilepsy Research · doi:10.1016/0920-1211(95)00077-1 · Cited by 198 · cited 1×
“LEV was also effective in animal models of chronic epilepsy, including genetic models (Genetic Absence Epilepsy Rat from Strasbourg, GAERS) and WAG/Rij rats [209,210], as well as in a rodent model of neonatal hypoxic seizures, where LEV pretreatment (50 mg/kg) resulted in a decrease in both behavioral seizure duration…”
Grønborg, M., Pavlos, N. J., Brunk, I., Chua, J. J. E., Münster-Wandowski, A., Riedel, D., Ahnert-Hilger, G., Urlaub, H., & Jahn, R. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4074-09.2010 · Cited by 194
Ambrogini, P., Torquato, P., Bartolini, D., Albertini, M. C., Lattanzi, D., Di Palma, M., Marinelli, R., Betti, M., Minelli, A., Cuppini, R., et al. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.01.026 · Cited by 185
Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H. (2016) · CNS Drugs · doi:10.1007/s40263-016-0384-x · Cited by 184 · cited 5×
“On the other hand, two hypotheses have been made to explain how LEV could reach the SV2A protein: (1) by diffusion across cellular membranes [8] and (2) by binding to SV2A during the synaptic vesicles cycle [122,123] (Figure 4).”
BackgroundInfluentialSV2 Renders Primed Synaptic Vesicles Competent for Ca2+-Induced Exocytosis
Chang, W.-P., & Südhof, T. C. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4521-08.2009 · Cited by 176 · cited 1×
“LEV may inhibit epileptogenesis through an increase in the suppressive effect of SV2A: (1) DKO mice (SV2A and SV2B) showed an increase in synaptic transmission during repetitive presynaptic fiber excitation [110] (2) in amygdala and corneal kindling epilepsy models, SV2A (+/−) mice show accelerated epileptogenesis [12…”
BackgroundReactive Glia Inflammatory Signaling Pathways and Epilepsy
Sanz, P., & Garcia-Gimeno, M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114096 · Cited by 176
Neuropharmacology of Antiseizure Drugs
Hakami, T. (2021) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12196 · Cited by 172 · cited 1×
“Nowadays, LEV is a broad-spectrum drug used alone and along with other medications for both focal-onset and generalized-onset seizures control [26].”
BackgroundNicolas, J., Hannestad, J., Holden, D., Kervyn, S., Nabulsi, N., Tytgat, D., Huang, Y., Chanteux, H., Staelens, L., Matagne, A., et al. (2016) · Epilepsia · doi:10.1111/epi.13267 · Cited by 169 · cited 3×
“In vitro studies performed on Caco-2 cells showed that LEV is permeable to membranes despite its low lipophilicity [124].”
BackgroundInfluentialCotrafficking of SV2 and synaptotagmin at the synapse
Yao, J., Nowack, A., Kensel-Hammes, P., Gardner, R. G., & Bajjalieh, S. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4781-09.2010 · Cited by 164 · cited 1×
“The Y46 residue of SV2A serves as a receptor for clathrin adaptor proteins; thus, SV2A via an interaction with both SYT-1 and clathrin adaptors may regulate the adequate trafficking of SYT-1 and, in consequence, the Ca2+-stimulated fusion [111,117,118].”
BackgroundGlien, M., Brandt, C., Potschka, H., & Löscher, W. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.18101.x · Cited by 161 · cited 2×
“Interestingly, the individual responses of the rats during two weeks of treatment varied markedly from full seizure control to no effect [203], likewise occurring in epileptic patients [194].”
BackgroundEfficacy and Safety of Levetiracetam in Children with Partial Seizures: An Open‐label Trial
Glauser, T. A., Pellock, J. M., Bebin, E. M., Fountain, N. B., Ritter, F. J., Jensen, C. M., & Shields, W. D. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.13101.x · Cited by 160 · cited 1×
“In an open-label study of adjunctive LEV therapy (at 20–40 mg/kg/day) in children (aged 6–12 years) with treatment-resistant focal-onset seizures, LEV protocols (4-week baseline, 6-week titration phase an 8-week evaluation phase) were effective, safe, and well tolerated [40].”
BackgroundLevetiracetam: The Preclinical Profile of a New Class of Antiepileptic Drugs?
Klitgaard, H. (2001) · Epilepsia · doi:10.1111/j.1528-1167.2001.00003.x · Cited by 148 · cited 2×
“The action of LEV to protect selectively against seizures in chronic models distinguishes it from other AEDs that act in both normal and “epileptic” animals [200].”
BackgroundEfficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery
Milligan, T. A., Hurwitz, S., & Bromfield, E. B. (2008) · Neurology · doi:10.1212/01.wnl.0000324624.52935.46 · Cited by 142 · cited 1×
“In a retrospective study of patients followed for one year receiving LEV (doses from 500 mg to 3000 mg a day; most frequent dose being 1000 mg a day) or phenytoin (doses from 200 to 800 mg a day, being the most frequent 300 mg) after supratentorial craniotomy, LEV treatment demonstrated a non-significant reduction in…”
BackgroundAntiepileptic drugs as a possible neuroprotective strategy in brain ischemia
Calabresi, P., Cupini, L. M., Centonze, D., Pisani, F., & Bernardi, G. (2003) · Annals of Neurology · doi:10.1002/ana.10603 · Cited by 140 · cited 1×
“Moreover, GABAergic neurotransmission is decreased during brain ischemia and epilepsy [257], therefore strategies that enhanced it, may be result in decrease in cellular damage.”
BackgroundThe holy grail of epilepsy prevention: Preclinical approaches to antiepileptogenic treatments
Löscher, W. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.04.011 · Cited by 137 · cited 1×
“Recently, LEV has been catalogued as a multitarget drug with interesting properties that are able to address some of the current necessities in epilepsy and in other conditions [25].”
BackgroundIntracellular Calcium Increase in Epileptiform Activity: Modulation by Levetiracetam and Lamotrigine
Pisani, A., Bonsi, P., Martella, G., De Persis, C., Costa, C., Pisani, F., Bernardi, G., & Calabresi, P. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.02204.x · Cited by 135 · cited 1×
“In addition, LEV (100 μM) provoked a partial reduction in P/Q-type HVA Ca2+ currents in the acutely isolated neocortical neurons [137].”
BackgroundVogl, C., Mochida, S., Wolff, C., Whalley, B. J., & Stephens, G. J. (2012) · Molecular Pharmacology · doi:10.1124/mol.111.076687 · Cited by 132 · cited 1×
“Interestingly, intracellular LEV administration caused (after 4 to 5 min of exposition) rapid inhibition of the Ca2+ current; this is consistent with a mechanism where LEV may interact directly with HVA Ca2+ channels, causing a reduction in synaptic transmission [19,114].”
BackgroundKovačević, J., Maroteaux, G., Schut, D., Loos, M., Dubey, M., Pitsch, J., Remmelink, E., Koopmans, B., Crowley, J., Cornelisse, L. N., et al. (2018) · Brain · doi:10.1093/brain/awy046 · Cited by 132 · cited 1×
“The de novo heterozygous mutations in STXBP1/Munc18-1 gene were implicated in the development of early infantile epileptic encephalopathies [180].”
BackgroundBehl, T., Makkar, R., Sehgal, A., Singh, S., Sharma, N., Zengin, G., Bungau, S., Andronie-Cioara, F. L., Munteanu, M. A., Brisc, M. C., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147432 · Cited by 131
Surges, R., Volynski, K. E., & Walker, M. C. (2008) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285608094212 · Cited by 129
Levetiracetam: a comprehensive review
Crepeau, A. Z., & Treiman, D. M. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.3 · Cited by 129 · cited 1×
“LEV is a second-generation anticonvulsant drug that has demonstrated a better tolerability and an improved efficiency compared other AEDs; thus, it has gradually become a first-choice drug [10].”
BackgroundMechanisms of Levetiracetam in the Control of Status Epilepticus and Epilepsy
Deshpande, L. S., & DeLorenzo, R. J. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00011 · Cited by 127 · cited 1×
“This effect was more potent than that in control neurons, suggesting that this may contribute to the antiepileptic effect of LEV [139,140].”
BackgroundAnimal Models Used in the Screening of Antiepileptic Drugs
Kupferberg, H. J. (2001) · Epilepsia · doi:10.1111/j.1528-1167.2001.00002.x · Cited by 127 · cited 15×
“Moreover, Wolking et al. investigated the genetic risk of rare variants for drug response to three AEDs (including LEV treatment for at least 1 year) through an analysis of the sequencing, genotyping, variant selection, and annotation of an epileptic cohort derived from the EpiPGX Consortium, to identify genetic bioma…”
BackgroundInfluentialAdjunctive levetiracetam in infants and young children with refractory partial‐onset seizures
Pina-Garza, J. E., Nordli, D. R., Rating, D., Yang, H., Schiemann‐Delgado, J., Duncan, B., & on behalf of the Levetiracetam N01009 Study Group (2009) · Epilepsia · doi:10.1111/j.1528-1167.2008.01981.x · Cited by 126 · cited 1×
“5 mg/kg/day) was effective and well tolerated [41].”
BackgroundAntioxidants as a Preventive Treatment for Epileptic Process: A Review of the Current Status
Martinc, B., Grabnar, I., & Vovk, T. (2015) · Current Neuropharmacology · doi:10.2174/1570159x12666140923205715 · Cited by 125 · cited 1×
“For example, the use of antioxidants can prevent the epileptic process in animal seizure models [267] and in a recent work, we showed that valproic acid, administered by 12 months without interruption acts as an antioxidant in children diagnosed with epilepsy decreasing oxidative markers as malondialdehyde (MDA, a lip…”
BackgroundSynaptic vesicle protein 2A: basic facts and role in synaptic function
Mendoza‐Torreblanca, J. G., Vanoye‐Carlo, A., Phillips‐Farfán, B. V., Carmona‐Aparicio, L., & Gómez‐Lira, G. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12360 · Cited by 124 · cited 2×
“On the other hand, two hypotheses have been made to explain how LEV could reach the SV2A protein: (1) by diffusion across cellular membranes [8] and (2) by binding to SV2A during the synaptic vesicles cycle [122,123] (Figure 4).”
BackgroundSelf-citationHansen, C. C., Ljung, H., Brodtkorb, E., & Reimers, A. (2018) · Behavioural Neurology · doi:10.1155/2018/2064027 · Cited by 124 · cited 17×
“Moreover, Wolking et al. investigated the genetic risk of rare variants for drug response to three AEDs (including LEV treatment for at least 1 year) through an analysis of the sequencing, genotyping, variant selection, and annotation of an epileptic cohort derived from the EpiPGX Consortium, to identify genetic bioma…”
BackgroundInfluentialGibbs, J. E., Walker, M. C., & Cock, H. R. (2006) · Epilepsia · doi:10.1111/j.1528-1167.2006.00454.x · Cited by 123
Lee, C.-Y., Chen, C., & Liou, H. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00463.x · Cited by 121 · cited 2×
“aptic calcium channels and the decrease in glutamate decrease preferentially [217].”
BackgroundResultMice with a Targeted Disruption of the Cl−/HCO3− Exchanger AE3 Display a Reduced Seizure Threshold
Hentschke, M., Wiemann, M., Hentschke, S., Kurth, I., Hermans-Borgmeyer, I., Seidenbecher, T., Jentsch, T. J., Gal, A., & Hübner, C. A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.1.182-191.2006 · Cited by 119
Levetiracetam is Neuroprotective in Murine Models of Closed Head Injury and Subarachnoid Hemorrhage
Wang, H., Gao, J., Lassiter, T. F., McDonagh, D. L., Sheng, H., Warner, D. S., Lynch, J., & Laskowitz, D. T. (2006) · Neurocritical Care · doi:10.1385/ncc:5:1:71 · Cited by 118 · cited 1×
“In models of head trauma and hemorrhage in the subarachnoid space, the use of LEV in mice at a dose of 54 mg/kg for 3 days showed an improvement in vestibular and motor functions, in addition to a reduction in neuronal histological damage [251].”
MethodSteinhoff, B. J., Klein, P., Klitgaard, H., Laloyaux, C., Moseley, B. D., Ricchetti-Masterson, K., Rosenow, F., Sirven, J. I., Smith, B., Stern, J. M., et al. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2021.107939 · Cited by 118 · cited 15×
“Moreover, Wolking et al. investigated the genetic risk of rare variants for drug response to three AEDs (including LEV treatment for at least 1 year) through an analysis of the sequencing, genotyping, variant selection, and annotation of an epileptic cohort derived from the EpiPGX Consortium, to identify genetic bioma…”
BackgroundInfluentialHanon, É., & Klitgaard, H. (2001) · Seizure · doi:10.1053/seiz.2000.0511 · Cited by 118 · cited 1×
“The neuroprotective effect of LEV has also been evaluated in models of focal cerebral ischemia, where it was found to be highly effective in reducing the infarct volume without altered body temperature, with better results than MK-801 (dizocilpine, non-competitive N-methyl-D-aspartic acid antagonist) [248].”
ResultNazıroğlu, M., & Yürekli, V. A. (2013) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-013-9936-5 · Cited by 117 · cited 1×
“However, the antioxidant effect of AEDs is still a matter of debate [269].”
BackgroundKaminski, R. M., Gillard, M., Leclercq, K., Hanon, E., Lorent, G., Dassesse, D., Matagne, A., & Klitgaard, H. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2009.02089.x · Cited by 116 · cited 2×
“LEV may inhibit epileptogenesis through an increase in the suppressive effect of SV2A: (1) DKO mice (SV2A and SV2B) showed an increase in synaptic transmission during repetitive presynaptic fiber excitation [110] (2) in amygdala and corneal kindling epilepsy models, SV2A (+/−) mice show accelerated epileptogenesis [12…”
BackgroundThe Synaptic Vesicle Glycoprotein 2: Structure, Function, and Disease Relevance
Stout, K. A., Dunn, A. R., Hoffman, C., & Miller, G. W. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00351 · Cited by 112 · cited 2×
“[8,91,119]; then, LEV would act as improver of synaptic vesicle exocytosis.”
BackgroundProlonged Exposure to Levetiracetam Reveals a Presynaptic Effect on Neurotransmission
Yang, X., Weisenfeld, A., & Rothman, S. M. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2006.01132.x · Cited by 111 · cited 1×
“In contrast, LEV decreased excitatory and inhibitory synaptic currents in an in vitro study of whole cell patch recordings, which suggest that LEV binds to SV2A and reduces presynaptic neurotransmitter release [122,216].”
BackgroundMeehan, A. L., Yang, X., McAdams, B. D., Yuan, L., & Rothman, S. M. (2011) · Journal of Neurophysiology · doi:10.1152/jn.00279.2011 · Cited by 109 · cited 6×
“On the other hand, two hypotheses have been made to explain how LEV could reach the SV2A protein: (1) by diffusion across cellular membranes [8] and (2) by binding to SV2A during the synaptic vesicles cycle [122,123] (Figure 4).”
BackgroundInfluentialClinical Pharmacology and Pharmacokinetics of Levetiracetam
Wright, C., Downing, J., Mungall, D., Khan, O., Williams, A., Fonkem, E., Garret, D., Aceves, J., & Kirmani, B. F. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00192 · Cited by 109 · cited 1×
“The intravenous formulation has been approved for patients 16 years of age and older; however, off-label use in children for the management of acute seizures has produced positive results [51].”
BackgroundGualtieri, F., Manetti, D., Romanelli, M. N., & Ghelardini, C. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023396582 · Cited by 109 · cited 1×
“In the preliminary SAR studies, it was highlighted that the ethyl derivative of piracetam (etiracetam) had a distinctive pharmacological profile that led to its development as an anticonvulsant, while structural modifications to the 2-oxopyrrolidine ring resulted in different compounds of which only a few reached clin…”
BackgroundNeuroinflammation: A Signature or a Cause of Epilepsy?
Pracucci, E., Pillai, V., Lamers, D., Parra, R., & Landi, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136981 · Cited by 105
The adverse event profile of levetiracetam: A meta-analysis on children and adults
Verrotti, A., Prezioso, G., Sabatino, F. D., Franco, V., Chiarelli, F., & Zaccara, G. (2015) · Seizure · doi:10.1016/j.seizure.2015.07.004 · Cited by 103 · cited 1×
“LEV treatment can promote infections such as pharyngitis, nasopharyngitis, and rhinitis [48,54,55].”
BackgroundCosta, C., Martella, G., Picconi, B., Prosperetti, C., Pisani, A., Filippo, M. D., Pisani, F., Bernardi, G., & Calabresi, P. (2006) · Stroke · doi:10.1161/01.str.0000217303.22856.38 · Cited by 103
SV2A and SV2C contain a unique synaptotagmin-binding site
Schivell, A. E., Mochida, S., Kensel-Hammes, P., Custer, K. L., & Bajjalieh, S. (2005) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.12.011 · Cited by 102 · cited 1×
“The Y46 residue of SV2A serves as a receptor for clathrin adaptor proteins; thus, SV2A via an interaction with both SYT-1 and clathrin adaptors may regulate the adequate trafficking of SYT-1 and, in consequence, the Ca2+-stimulated fusion [111,117,118].”
BackgroundRepurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?
Klein, P., Friedman, A., Hameed, M. Q., Kaminski, R. M., Bar‐Klein, G., Klitgaard, H., Koepp, M. J., Jóźwiak, S., Prince, D. A., Rotenberg, A., et al. (2020) · Epilepsia · doi:10.1111/epi.16450 · Cited by 102 · cited 1×
“Antiepileptic drugs (AEDs; also named antiseizure drugs) efficiently control seizures, but only in about 2/3 of people with epilepsy [4]; moreover, during the last few years it has become clear that the current way of treating epilepsy with AEDs that only controls seizures is insufficient, since it does not cover the…”
BackgroundWood, M. D., & Gillard, M. (2017) · Epilepsia · doi:10.1111/epi.13638 · Cited by 101
Oliveira, A. A., Almeida, J. P., Freitas, R. D. M. O. F., Nascimento, V. S., Aguiar, L. M. V., Júnior, H. V. N., da Fonseca, F. N., Viana, G. S. D. B., de Sousa, F. C. F., & Fonteles, M. M. D. F. (2007) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9132-y · Cited by 101
AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro
Lange, F., Weßlau, K., Porath, K., Hörnschemeyer, M. F., Bergner, C., Krause, B. J., Mullins, C. S., Linnebacher, M., Köhling, R., & Kirschstein, T. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211644 · Cited by 100 · cited 1×
“In addition, it has been shown that LEV (18 and 180 μM) significantly decreases the gene expression of excitatory amino acid transporter 2, (EAAT2) in brain metastasis glioblastoma cells culture, indicating that LEV has a mechanism of action that decreases the recapture of glutamate from the extracellular space in bra…”
BackgroundLevetiracetam and brivaracetam: A review of evidence from clinical trials and clinical experience
Steinhoff, B. J., & Staack, A. M. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419873518 · Cited by 99 · cited 3×
“Although piracetam is a nootropic drug, LEV does not show significant nootropic effects; however, it was evaluated in epilepsy models since piracetam exhibited efficacy in the treatment of photo paroxysmal responses and myoclonus [15].”
BackgroundInfluentialKlein, P., Herr, D., Pearl, P. L., Natale, J. E., Levine, Z. T., Nogay, C., Sandoval, F., Trzcinski, S., Atabaki, S. M., Tsuchida, T. N., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.445 · Cited by 97 · cited 1×
“Even though, LEV treatment nonsignificantly reduced posttraumatic epilepsy cases, it was safe and well tolerated [232].”
BackgroundIs Mossy Fiber Sprouting a Potential Therapeutic Target for Epilepsy?
Cavarsan, C. F., Malheiros, J. M., Hamani, C., Najm, I., & Covolan, L. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.01023 · Cited by 97
Evans, A. K., & Lowry, C. A. (2007) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2007.00025.x · Cited by 96 · cited 1×
“β-carbolines congeners can act at the benzodiazepine recognition site of the GABAA receptor complex to inhibit GABA-stimulated chloride conductance (inverse agonist effect) [155,156] (Figure 4).”
BackgroundDose–response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy
Boon, P., Chauvel, P., Pohlmann‐Eden, B., Otoul, C., & Wroe, S. J. (2002) · Epilepsy Research · doi:10.1016/s0920-1211(01)00323-0 · Cited by 95 · cited 2×
“In a TLE model induced by kainic acid has been reported a rebound effect after rapid LEV withdrawal [302]; nevertheless, patients with refractory focal-onset seizures and withdrawal of LEV did not show this phenomenon [303].”
BackgroundIuchi, T., Kuwabara, K., Matsumoto, M., Kawasaki, K., Hasegawa, Y., & Sakaida, T. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308584 · Cited by 94 · cited 1×
“A prospective, randomized study with prophylactic LEV treatment (500 mg/body every 12 h until postoperative day 7) in the perioperative period, showed a reduction in seizure incidence [231].”
BackgroundNagarkatti, N., Deshpande, L. S., & DeLorenzo, R. J. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.02.076 · Cited by 93 · cited 3×
“Moreover, LEV acts through the ryanodine and IP3 receptors inhibiting Ca2+ release [142,143].”
BackgroundKruer, R. M., Harris, L. H., Goodwin, H. E., Kornbluth, J. A., Thomas, K. P., Slater, L. A., & Haut, E. R. (2013) · Journal of Critical Care · doi:10.1016/j.jcrc.2012.11.020 · Cited by 92 · cited 1×
“showed a decrease in seizure incidence seven days after TBI in patients treated with phenytoin and LEV [233].”
BackgroundDoheny, H. C., Ratnaraj, N., Whittington, M. A., Jefferys, J. G. R., & Patsalos, P. N. (1999) · Epilepsy Research · doi:10.1016/s0920-1211(98)00104-1 · Cited by 92
Generalized versus partial reflex seizures: A review
Italiano, D., Ferlazzo, E., Gasparini, S., Spina, E., Mondello, S., Labate, A., Gambardella, A., & Aguglia, U. (2014) · Seizure · doi:10.1016/j.seizure.2014.03.014 · Cited by 92 · cited 1×
“LEV has also shown good efficacy in patients with reflex seizures (for a review see [30]) and is probably the best new AED for the treatment of juvenile myoclonic epilepsy because of a high and sustained efficacy [31].”
BackgroundKlitgaard, H., & Pitkänen, A. (2003) · Epileptic Disorders · doi:10.1684/j.1950-6945.2003.tb00025.x · Cited by 91
Effects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindling model
Stratton, S. C., Large, C. H., Cox, B., Davies, G., & Hagan, R. M. (2003) · Epilepsy Research · doi:10.1016/s0920-1211(02)00254-1 · Cited by 89 · cited 2×
“[219] Rat amygdala kindling model 50 mg/kg i.”
BackgroundBirnstiel, S., Wülfert, E., & Beck, S. G. (1997) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/pl00005097 · Cited by 89 · cited 3×
“Abbreviations 3-Nitrotyrosine (3-NT); 8-Hydroxy-2-Deoxyguanosine (8-OHdG); Activator Protein-1 (AP-1); Adenosine-Triphosphate (ATP)-Binding Cassette Sub-Family B Member 1 (ABCB1); Alpha-Amino-3Hydroxy-5-Methyl-4-Isoxazole Propionic Acid (AMPA); Angiopoietin-2 (Tie-2); Antiepileptic Drugs (AEDs); Blood-Brain Barrier (B…”
Carunchio, I., Pieri, M., Ciotti, M. T., Albo, F., & Zona, C. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2006.00973.x · Cited by 89 · cited 2×
“This was confirmed by the administration of cyclothiazide, an AMPA positive allosteric modulator in these cells, since LEV decreased the amplitude of currents induced by cyclothiazide as well as diminished the amplitude and frequency of mEPSC [170].”
BackgroundFuller, K., Wang, Y. Y., Cook, M. J., Murphy, M. A., & D'Souza, W. J. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03563.x · Cited by 89 · cited 1×
“Furthermore, intravenous LEV for 3 days and oral regimen at 90 days has been proposed as an optional drug for the prevention of seizures and epilepsy in craniotomy and other neurosurgical interventions [236].”
BackgroundEffects of Levetiracetam on Tardive Dyskinesia: A Randomized, Double-Blind, Placebo-Controlled Study
Woods, S. W., Saksa, J. R., Baker, C. B., Cohen, S. J., & Tek, C. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0405 · Cited by 87 · cited 1×
“A randomized, double-blind, placebo-controlled study has shown LEV (500 mg/day to 3000 mg/day or placebo for 12 weeks) to be effective for tardive dyskinesia [82].”
BackgroundBrandt, C., Glien, M., Gastens, A. M., Fedrowitz, M., Bethmann, K., Volk, H. A., Potschka, H., & Löscher, W. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.05.001 · Cited by 87 · cited 2×
“Moreover, some reports have shown that LEV did not prevent acquired epilepsy when administered in post-SE animal models of TLE, although it did exert neuroprotective effects [225,246,247].”
BackgroundMethodNeurodegeneration and Pathology in Epilepsy: Clinical and Basic Perspectives
Farrell, J. S., Wolff, M. D., & Teskey, G. C. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-57193-5_12 · Cited by 87
de Souza, A. G., Chaves Filho, A. J. M., Souza Oliveira, J. V., de Souza, D. A. A., Lopes, I. S., de Carvalho, M. A. J., de Lima, K. A., Florenço Sousa, F. C., Mendes Vasconcelos, S. M., Macedo, D., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.066 · Cited by 87 · cited 1×
“The same observation was shown in the kindling model of epilepsy-induced by PTZ, where the nitrite, 8-OHdG, and lipoperoxidation levels were significantly reduced, and GSH, GPx, and SOD were increased for chronic treatment with LEV [273,274].”
BackgroundBrivaracetam: a rational drug discovery success story
Rogawski, M. A. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.221 · Cited by 86
Correlation of transcriptome profile with electrical activity in temporal lobe epilepsy
Arion, D., Sabatini, M., Unger, T., Pastor, J., Alonso-Nanclares, L., Ballesteros-Yáñez, I., García Sola, R., Muñoz, A., Mirnics, K., & DeFelipe, J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.12.012 · Cited by 86 · cited 1×
“In addition, it was observed in electrocorticography registers of epileptic patients an epileptiform electrical activity in the form of spikes, which has been associated with changes in gene expression [188,189].”
BackgroundPatterns of seizure activation after withdrawal of antiepileptic medication
Marciani, M. G., Gotman, J., Andermann, F., & Olivier, A. (1985) · Neurology · doi:10.1212/wnl.35.11.1537 · Cited by 86
Levetiracetam monotherapy for late poststroke seizures in the elderly
Kutlu, G., Gömceli, Y. B., Ünal, Y., & İnan, L. E. (2008) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2008.04.025 · Cited by 86 · cited 2×
“suffered an injury, for example, in brain ischemia, which has been also associated with post-traumatic epilepsy [187,241].”
BackgroundHejazi, R. A., Reddymasu, S. C., Namin, F., Lavenbarg, T., Foran, P., & McCallum, R. W. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181ac6489 · Cited by 84 · cited 1×
“Clinical studies have shown in adult patients and elderly patients that LEV (initial dose was 500 mg/day and increased in 500 mg increments, n a twice daily dosing regimen, to a median dose of 1000 mg per day) is effective for prophylaxis against cyclic vomiting syndrome episodes [86,87].”
BackgroundStienen, M. N., Haghikia, A., Dambach, H., Thöne, J., Wiemann, M., Gold, R., Chan, A., Dermietzel, R., Faustmann, P. M., Hinkerohe, D., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01038.x · Cited by 84 · cited 4×
“Abbreviations 3-Nitrotyrosine (3-NT); 8-Hydroxy-2-Deoxyguanosine (8-OHdG); Activator Protein-1 (AP-1); Adenosine-Triphosphate (ATP)-Binding Cassette Sub-Family B Member 1 (ABCB1); Alpha-Amino-3Hydroxy-5-Methyl-4-Isoxazole Propionic Acid (AMPA); Angiopoietin-2 (Tie-2); Antiepileptic Drugs (AEDs); Blood-Brain Barrier (B…”
BackgroundInfluentialKılıçdağ, H., Dağlıoğlu, K., Erdoğan, Ş., Güzel, A., Sencar, L., Polat, S., & Zorludemir, S. (2012) · Early Human Development · doi:10.1016/j.earlhumdev.2012.12.002 · Cited by 84 · cited 1×
“Likewise, in neonatal rat model hypoxic– ischemic brain injury, seven days of LEV treatment (40 mg/kg/day) significantly decreased the numbers of TUNEL positive apoptotic cells in both the hippocampus and cerebral cortex [249].”
BackgroundYan, H., Ji‐qun, C., Ishihara, K., Nagayama, T., Serikawa, T., & Sasa, M. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.35204.x · Cited by 84 · cited 1×
“[221] Spontaneously epileptic rat 80 mg/kg/day i.”
Tong, X., & Patsalos, P. N. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704141 · Cited by 83
Helmstaedter, C., Mihov, Y., Toliat, M. R., Thiele, H., Nuernberg, P., Schoch, S., Surges, R., Elger, C. E., Kunz, W. S., & Hurlemann, R. (2013) · Epilepsia · doi:10.1111/j.1528-1167.2012.03603.x · Cited by 82 · cited 1×
“Finally, in another study, the presence of rs1611115, rs4680 and rs1800497 polymorphisms with adverse psychotropic side effects of LEV in patients with chronic epilepsy was found to be related with a decrease in dopaminergic activity [195].”
BackgroundLevetiracetam Reverses Synaptic Deficits Produced by Overexpression of SV2A
Nowack, A., Malarkey, E. B., Yao, J., Bleckert, A., Hill, J., & Bajjalieh, S. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029560 · Cited by 81 · cited 2×
“Moreover, treatment with LEV blocked both the development of a seizure phenotype [130] and increased the hippocampal expression of SV2A [131] in kindled mice and in primary cultures of hippocampal neurons overexpressing SV2A [121].”
BackgroundUse of levetiracetam to treat tics in children and adolescents with Tourette syndrome
Awaad, Y., Michon, A. M., & Minarik, S. (2005) · Movement Disorders · doi:10.1002/mds.20385 · Cited by 81
Levetiracetam reduces abnormal network activations in temporal lobe epilepsy
Wandschneider, B., Stretton, J., Sidhu, M. K., Centeno, M., Kozák, L. R., Symms, M. R., Thompson, P. J., Duncan, J. S., & Koepp, M. J. (2014) · Neurology · doi:10.1212/wnl.0000000000000910 · Cited by 81 · cited 1×
“Moreover, a recent study indicated that epileptic patients treated with LEV showed increased functional connectivity compared to healthy subjects [238], relating to normalization of left medial temporal lobe deactivation during verbal performance [239].”
BackgroundKlitgaard, H., Matagne, A., Grimée, R., Vanneste-Goemaere, J., & Mǎrgineanu, D.-G. (2003) · Seizure · doi:10.1016/s1059131102001930 · Cited by 80 · cited 11×
“Histological examination with cresyl violet staining showed that a high dose of LEV (500 mg/kg for 28 days) significantly reduced the number of neuronal cells lost in the CA1 and CA3 and DG areas at two days after SE and it protected against the sequence of excitotoxic events induced by vasogenic edema [22].”
BackgroundInfluentialLevetiracetam in the Prophylaxis of Migraine With Aura
Brighina, F., Palermo, A., Aloisio, A., Francolini, M., Giglia, G., & Fierro, B. (2006) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000236766.08409.03 · Cited by 79 · cited 1×
“reported that LEV (dosage of 1000 mg/day for 6 months) could improve pain in patients with migraines [66].”
BackgroundImplications of antiinflammatory properties of the anticonvulsant drug levetiracetam in astrocytes
Haghikia, A., Ladage, K., Hinkerohe, D., Vollmar, P., Heupel, K., Dermietzel, R., & Faustmann, P. M. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21639 · Cited by 79 · cited 1×
“In addition, LEV treatment restored impaired astroglial gap junction coupling, along with repolarization of the membrane rest potential, under inflammatory conditions [293], and it increased the expression of growth factor beta 1 (GF-β1) [292].”
BackgroundRossi, S., Mataluni, G., Codecà, C., Fiore, S., Buttari, F., Musella, A., Castelli, M., Bernardi, G., & Centonze, D. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02496.x · Cited by 75 · cited 1×
“reported the beneficial effects of LEV (3000 mg/day for 6 weeks) in the control of central neuropathic pain symptoms in patients with multiple sclerosis (MS) [13,14].”
BackgroundTokudome, K., Okumura, T., Shimizu, S., Mashimo, T., Takizawa, A., Serikawa, T., Terada, R., Ishihara, S., Kunisawa, N., Sasa, M., et al. (2016) · Scientific Reports · doi:10.1038/srep27420 · Cited by 75 · cited 1×
“These data agree with the observations of a great co-expression between SV2A and GABAergic neurons in the amygdala and hippocampus [163,164,166,167].”
ResultLöscher, W., Hönack, D., & Bloms‐Funke, P. (1996) · Brain Research · doi:10.1016/0006-8993(96)00587-2 · Cited by 75 · cited 5×
“Moreover, LEV modified GABA turnover by reducing it in the striatum but increasing it in the cortex and hippocampus [151].”
BackgroundResultInfluentialZonisamide or Levetiracetam for Adults With Cyclic Vomiting Syndrome: A Case Series
Clouse, R. E., Sayuk, G. S., Lustman, P. J., & Prakash, C. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.10.004 · Cited by 74 · cited 1×
“Clinical studies have shown in adult patients and elderly patients that LEV (initial dose was 500 mg/day and increased in 500 mg increments, n a twice daily dosing regimen, to a median dose of 1000 mg per day) is effective for prophylaxis against cyclic vomiting syndrome episodes [86,87].”
BackgroundActivity‐dependent Gene Expression Correlates with Interictal Spiking in Human Neocortical Epilepsy
Rakhade, S. N., Shah, A. K., Agarwal, R., Yao, B., Asano, E., & Loeb, J. A. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01294.x · Cited by 71 · cited 1×
“In addition, it was observed in electrocorticography registers of epileptic patients an epileptiform electrical activity in the form of spikes, which has been associated with changes in gene expression [188,189].”
BackgroundPalma, E., Ragozzino, D., Angelantonio, S. D., Mascia, A., Maiolino, F., Manfredi, M., Cantore, G., Esposito, V., Gennaro, G. D., Quarato, P. P., et al. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01131.x · Cited by 71 · cited 4×
“Meanwhile, in the tissue of patients, LEV inhibited the GABA-current run-down in the hippocampus and neocortex but was ineffective in the hippocampal subiculum [154].”
BackgroundInfluentialKim, J., Choi, H., Song, H., Jo, S., Kim, D., Choi, S., Kim, Y.-I., & Kang, T. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.01.018 · Cited by 70 · cited 3×
“Recent evidence in different animal models, suggests that LEV exerts neuroprotective effects via anti-inflammatory and antioxidant effects [178,244,270].”
Backgroundngehagen, M., Margineanu, D. G., Ben‐Menachem, E., ck, L. R. N., Hansson, E., & Klitgaard, H. (2003) · Neuroreport · doi:10.1097/00001756-200303030-00035 · Cited by 70 · cited 2×
“LEV significantly reduced the Ca2+ transients induced by caffeine (a ryanodine receptor activator) in cultured rat hippocampal neurons [141,142].”
BackgroundSander, T., Toliat, M. R., Heils, A., Leschik, G., Becker, C., Rüschendorf, F., Rohde, K., Mundlos, S., & Nürnberg, P. (2002) · Epilepsy Research · doi:10.1016/s0920-1211(02)00152-3 · Cited by 69 · cited 1×
“Several studies have suggested that the Na+-independent Cl/HCO3 exchanger, AE3, may modulate seizure susceptibility [171,173].”
BackgroundLevetiracetam: The Preclinical Profile of a New Class of Antiepileptic Drugs?
Klitgaard, H. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.00003.x · Cited by 68
Epilepsy-associated alterations in hippocampal excitability
Navidhamidi, M., Ghasemi, M., & Mehranfard, N. (2017) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0059 · Cited by 66 · cited 1×
“Multiple AEDs act on its GABAA receptor to increase inhibition and thereby controlling the aberrant neuronal activity and seizures [144].”
BackgroundShetty, A. K. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00172 · Cited by 65
Pérez‐Pérez, D., Frías‐Soria, C. L., & Rocha, L. (2019) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2019.07.031 · Cited by 65 · cited 1×
“Antiepileptic drugs (AEDs; also named antiseizure drugs) efficiently control seizures, but only in about 2/3 of people with epilepsy [4]; moreover, during the last few years it has become clear that the current way of treating epilepsy with AEDs that only controls seizures is insufficient, since it does not cover the…”
BackgroundSynaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma
de Groot, M., Aronica, E., Heimans, J. J., & Reijneveld, J. C. (2011) · Neurology · doi:10.1212/wnl.0b013e318228c110 · Cited by 64 · cited 1×
“Moreover, in the tumor and peritumoral tissues of glioma of patients with epilepsy, SV2A expression levels correlated with the clinical efficacy of LEV [129].”
BackgroundBinding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain
Gillard, M. R., Fuks, B., Michel, P., Vertongen, P., Massingham, R., & Chatelain, P. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.032 · Cited by 61
Bennett, B. A., Matagne, A., Michel, P., Leonard, M., Cornet, M., Meeus, M.-A., & Toublanc, N. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2006.11.014 · Cited by 61 · cited 1×
“As a consequence of SAR studies, BRIV, the 4-(R)-propyl LEV analog, emerged as an promising antiepileptic candidate [16]; later, seletracetam appeared, which was a 4-(R)-2,2-difluoroethenyl LEV analog with a 10-fold greater affinity for SV2A than LEV [92] (Figure 1A).”
BackgroundLevetiracetam for managing neurologic and psychiatric disorders
Farooq, M. U., Bhatt, A., Majid, A., Gupta, R., Khasnis, A., & Kassab, M. Y. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070607 · Cited by 60
Temporal lobe epilepsy-induced neurodegeneration and cognitive deficits: Implications for aging
Vrinda, M., Arun, S., Srikumar, B. N., Kutty, B. M., & Shankaranarayana Rao, B. S. (2019) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2018.02.005 · Cited by 60
Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases
Irwin, M. H., Moos, W. H., Faller, D. V., Steliou, K., & Pinkert, C. A. (2016) · Drug Development Research · doi:10.1002/ddr.21294 · Cited by 59 · cited 2×
“tive genes and antioxidant response elements [298,299] and has been demonstrated that LEV”
BackgroundDramatic effect of levetiracetam in early-onset epileptic encephalopathy due to STXBP1 mutation
Dilena, R., Striano, P., Traverso, M., Viri, M., Cristofori, G., Tadini, L., Barbieri, S., Romeo, A., & Zara, F. (2015) · Brain and Development · doi:10.1016/j.braindev.2015.07.002 · Cited by 59
Sugaya, Y., Maru, E., Kudo, K., Shibasaki, T., & Kato, N. (2010) · Brain Research · doi:10.1016/j.brainres.2010.06.061 · Cited by 59 · cited 4×
“[224] Rat kainate-induced SE model 100 mg/kg, i.”
BackgroundInfluentialLévesque, M., Behr, C., & Avoli, M. (2014) · Seizure · doi:10.1016/j.seizure.2014.11.008 · Cited by 59 · cited 10×
“Histological examination with cresyl violet staining showed that a high dose of LEV (500 mg/kg for 28 days) significantly reduced the number of neuronal cells lost in the CA1 and CA3 and DG areas at two days after SE and it protected against the sequence of excitotoxic events induced by vasogenic edema [22].”
BackgroundResultInfluentialSvichar, N., Esquenazi, S., Chen, H.-Y., & Chesler, M. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.6088-10.2011 · Cited by 59 · cited 1×
“Acid loading is mediated by Na+-independent Cl/HCO3 exchangers [171,172].”
BackgroundVaroğlu, A. O., Yıldırım, A., Aygül, R., Gündoğdu, Ö. L., & Sahin, Y. N. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181d1e133 · Cited by 58 · cited 1×
“Several clinical studies have shown that LEV modified the antioxidant/oxidant status in patients with epilepsy [284,285], this AED increased the oxidative state (MDA, 15F2t-isoprostane and 8-OHdG markers) in patients diagnosed with epilepsy [286,287], and significantly increase the 8-OHdG levels in combination with va…”
BackgroundCai, J., Ishihara, K., Nagayama, T., Serikawa, T., & Sasa, M. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.29604.x · Cited by 57 · cited 1×
“Furthermore, long-lasting seizure protection by LEV after cessation of treatment was observed [204].”
BackgroundAntiepileptic effects of levetiracetam in a rodent neonatal seizure model
Talos, D. M., Chang, M., Kosaras, B., Fitzgerald, E., Murphy, A., Folkerth, R. D., & Jensen, F. E. (2013) · Pediatric Research · doi:10.1038/pr.2012.151 · Cited by 56 · cited 1×
“LEV was also effective in animal models of chronic epilepsy, including genetic models (Genetic Absence Epilepsy Rat from Strasbourg, GAERS) and WAG/Rij rats [209,210], as well as in a rodent model of neonatal hypoxic seizures, where LEV pretreatment (50 mg/kg) resulted in a decrease in both behavioral seizure duration…”
Synaptic vesicle protein 2: A multi-faceted regulator of secretion
Ciruelas, K., Marcotulli, D., & Bajjalieh, S. M. (2019) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.02.003 · Cited by 55 · cited 1×
“(3) LEV may enhance the role of SV2A in modulating the expression and trafficking of SYT, since LEV restores the normal levels of these protein expressions in neurons to overexpress SV2A [120,121].”
BackgroundQiao, M., Cui, H.-T., Zhao, L.-Z., Miao, J., & Chen, Q.-X. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.747745 · Cited by 55 · cited 2×
“In newborns, the usual dose of LEV has been reported between 20 and 60 mg/kg/day for the treatment of neonatal seizures [49].”
BackgroundCataldi, M., Lariccia, V., Secondo, A., Renzo, G. D., & Annunziato, L. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.079327 · Cited by 54 · cited 2×
“Moreover, LEV acts through the ryanodine and IP3 receptors inhibiting Ca2+ release [142,143].”
BackgroundGu, J., Lynch, B. A., Anderson, D., Klitgaard, H., Lu, S., Elashoff, M., Ebert, U., Potschka, H., & Löscher, W. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2003.03106.x · Cited by 54 · cited 4×
“5 days per week) [175,176] and related to mossy fiber sprouting and consequently neu-”
BackgroundMethodInfluentialMazzuferi, M., Palma, E., Martinello, K., Maiolino, F., Roseti, C., Fucile, S., Fabene, P. F., Schio, F., Pellitteri, M., Sperk, G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914710107 · Cited by 54
Husum, H., Bolwig, T. G., Sánchez, C., Mathé, A. A., & Hansen, S. H. (2004) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2003.12.004 · Cited by 54 · cited 3×
“5 days per week) [175,176] and related to mossy fiber sprouting and consequently neu-”
BackgroundItoh, K., Ishihara, Y., Komori, R., Nochi, H., Taniguchi, R., Chiba, Y., Ueno, M., Takata-Tsuji, F., Dohgu, S., & Kataoka, Y. (2016) · Brain Research · doi:10.1016/j.brainres.2016.09.038 · Cited by 54 · cited 3×
“Recent evidence in different animal models, suggests that LEV exerts neuroprotective effects via anti-inflammatory and antioxidant effects [178,244,270].”
BackgroundTaylor, S., Heinrichs, R. J., Janzen, J. M., & Ehtisham, A. (2010) · Neurocritical Care · doi:10.1007/s12028-010-9341-6 · Cited by 53 · cited 1×
“In a study of intracerebral hemorrhage patients, the prophylactic use of LEV (delivered at a rate of 500–2000 mg/d) improved the prognosis and was more effective than phenytoin (15–20 mg/kg) in preventing seizures, without affecting cognitive ability [237].”
BackgroundEffect of levetiracetam in patients with epilepsy and interictal epileptiform discharges
Stodieck, S. R. G., Steinhoff, B. J., Kolmsee, S., & van Rijckevorsel, K. (2001) · Seizure · doi:10.1053/seiz.2001.0582 · Cited by 53 · cited 1×
“found a reduction in interictal spikes rates in CA3, entorhinal cortex, DG and subiculum in LEV-treated rats (300 mg/kg/day for 2 weeks) without seizures [21], similar observations were performed in patients with focal-onset seizures and acute (500 mg twice daily) or chronic treatment with LEV (individualized, 500–100…”
ResultChristensen, K. V., Leffers, H., Watson, W. P., Sánchez, C., Kallunki, P., & Egebjerg, J. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-9 · Cited by 53 · cited 1×
“The decrease in the expression of both genes was parallel to the antiseizure effect of the drug [177].”
BackgroundMǎrgineanu, D.-G., Matagne, A., Kaminski, R. M., & Klitgaard, H. (2008) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2008.07.006 · Cited by 52 · cited 3×
“Thus, if LEV can inhibit hypersynchronous neuronal activity by reducing the epileptiform activity-induced population spikes in CA3 [148] and in dentate gyrus (DG) [190], this suggests that LEV could modulate the expression of genes, as we mentioned above.”
BackgroundMicov, A. M., Tomic´, M. A., Popović, B. V., & Stepanović-Petrović, R. M. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00877.x · Cited by 50
Anticonvulsive and antiepileptogenic effects of levetiracetam in the audiogenic kindling model
Vinogradova, L. V., & van Rijn, C. M. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01594.x · Cited by 50 · cited 1×
“Vinogradova and van Rijn [220] Rat audiogenic kindling model 50 mg/kg i.”
BackgroundWakita, M., Kotani, N., Kogure, K., & Akaike, N. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.208751 · Cited by 50 · cited 1×
“Then, LEV reversed the Zn2+ induced suppression of GABAA receptors, resulting in a decrease in glutamatergic excitatory transmission [158].”
BackgroundLevetiracetam as an antiepileptic, neuroprotective, and hyperalgesic drug
Alfaro-Rodríguez, A., Cortes-Altamirano, J. L., Olmos-Hernández, A. S., Bonilla‐Jaime, H., Bandala, C., & González-Maciel, A. (2016) · Neurology India · doi:10.4103/0028-3886.193801 · Cited by 50 · cited 3×
“pointed out that the mechanism of action of LEV comprises a cascade of effects that in the first instance, are exerted by binding to the SV2A protein, but its pharmacodynamics involve various molecular targets that must be integrated into a single mechanism of action by a single pathway [11].”
BackgroundInfluentialSelf-citationLevetiracetam for Seizure Prophylaxis in Neurocritical Care: A Systematic Review and Meta-analysis
Fang, T., Valdes, E., & Frontera, J. A. (2021) · Neurocritical Care · doi:10.1007/s12028-021-01296-z · Cited by 50
Belcastro, V., Pierguidi, L., & Tambasco, N. (2010) · Brain and Development · doi:10.1016/j.braindev.2010.06.008 · Cited by 49 · cited 4×
“There is evidence that in HeLa cells, the main metabolite of LEV blocks histone deacetylases which catalyze the hydrolysis of acetyl groups from the lysine of some proteins, such as histone tails, inducing chromatin condensation and inhibiting gene transcription [187].”
BackgroundInfluential(2000) · Epilepsia · doi:10.1111/j.1499-1654.2000.001499.x · Cited by 47 · cited 1×
“, at a dose of 108 mg/kg for 21 days) decreased the anticonvulsant efficacy indicating a development of tolerance [206].”
BackgroundYan, H., Ishihara, K., Seki, T., Hanaya, R., Kurisu, K., Arita, K., Serikawa, T., & Sasa, M. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2012.10.006 · Cited by 47
Stepanović-Petrović, R. M., Micov, A. M., Tomic´, M. A., & Ugrešić, N. D. (2012) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e31826c7fc2 · Cited by 47 · cited 3×
“In contrast, the administration of all antagonists decreased this effect of LEV [168,169].”
BackgroundInfluentialRadic, J. A. E., Chou, S., Du, R., & Lee, J. W. (2014) · Neurocritical Care · doi:10.1007/s12028-013-9951-x · Cited by 47 · cited 1×
“reported that LEV (1000 mg intravenous loading dose, followed by a dose of 500–1000 mg intravenous or orally twice daily) prevented clinical and/or electrographic seizures after acute/subacute subdural hematoma diagnosis [234].”
BackgroundSarangi, S. C., Kakkar, A. K., Kumar, R. N., & Gupta, Y. K. (2016) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.193296 · Cited by 47 · cited 1×
“05) was observed in the homogenized brain tissue of rats after the administration for 45 days of this drug [282].”
BackgroundLeclercq, K., Matagne, A., Provins, L., Klitgaard, H., & Kaminski, R. M. (2020) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.261222 · Cited by 46 · cited 8×
“Then, towards the end of the 2000s, the development of seletracetam was halted, but BRIV was successfully brought to the market [93].”
BackgroundInfluentialA randomized, placebo‐controlled trial of levetiracetam in central pain in multiple sclerosis
Falah, M., Madsen, C., Holbech, J. V., & Sindrup, S. H. (2012) · European Journal of Pain · doi:10.1002/j.1532-2149.2011.00073.x · Cited by 46 · cited 1×
“reported the beneficial effects of LEV (3000 mg/day for 6 weeks) in the control of central neuropathic pain symptoms in patients with multiple sclerosis (MS) [13,14].”
BackgroundItoh, K., Inamine, M., Oshima, W., Kotani, M., Chiba, Y., Ueno, M., & Ishihara, Y. (2015) · Brain Research · doi:10.1016/j.brainres.2015.03.005 · Cited by 46 · cited 3×
“Histological examination with cresyl violet staining showed that a high dose of LEV (500 mg/kg for 28 days) significantly reduced the number of neuronal cells lost in the CA1 and CA3 and DG areas at two days after SE and it protected against the sequence of excitotoxic events induced by vasogenic edema [22].”
BackgroundLevetiracetam inhibits neurotransmitter release associated with CICR
Fukuyama, K., Tanahashi, S., Nakagawa, M., Yamamura, S., Motomura, E., Shiroyama, T., Tanii, H., & Okada, M. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.03.056 · Cited by 46 · cited 1×
“In addition, by K+-evoked depolarization with microdialysis technique, LEV inhibited the release of biogenic amines, GABA, and L-glutamate in the medial prefrontal cortex of control rats [149]; however, in epileptic rats treated with LEV for one week, the K+-evoked depolarization induced a preferential increase in GAB…”
Levetiracetam prevents kindling‐induced asymmetric accumulation of hippocampal 7S SNARE complexes
Matveeva, E. A., Vanaman, T. C., Whiteheart, S. W., & Slevin, J. T. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01687.x · Cited by 45 · cited 1×
“Moreover, treatment with LEV blocked both the development of a seizure phenotype [130] and increased the hippocampal expression of SV2A [131] in kindled mice and in primary cultures of hippocampal neurons overexpressing SV2A [121].”
BackgroundSafdieh, J., & Ulloa, C. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s4844 · Cited by 44 · cited 1×
“LEV differs from classical AEDs since it does not share affinity with targets of other AEDs such as valproic acid, phenobarbital or benzodiazepines and does not work by the three classic routes of AEDs: sodium channel modulation, low-voltage-activated (T-type) calcium channel modulation and a direct GABAfacilitation […”
BackgroundWood, M., Daniels, V., Provins, L., Wolff, C., Kaminski, R. M., & Gillard, M. (2020) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.261149 · Cited by 44 · cited 1×
“1) to recombinant GABAA receptors [97].”
Levetiracetam in Patients With Impulsive Aggression
Mattes, J. A. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0218 · Cited by 44
Development of tolerance to levetiracetam in rats with chronic epilepsy
van Vliet, E. A., van Schaik, R., Edelbroek, P. M., Lopes, F. H. D. S., Wadman, W. J., & Gorter, J. A. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2007.01516.x · Cited by 44 · cited 1×
“In chronic epileptic rats treated repeatedly with LEV (564 mg/kg/day 1 week via osmotic minipumps) show less severe seizure behavior during drug treatment [212].”
BackgroundBaysal, M., Ilgın, S., Kılıç, G., Kılıç, V., Uçarcan, Ş., & Atlı, Ö. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175990 · Cited by 44 · cited 1×
“), has been reported where this AED induces DNA damage in the rat testes and decrease GSH, SOD, and CAT levels after 70 days of treatment [283].”
BackgroundSong, H., Tufa, U., Chow, J., Sivanenthiran, N., Cheng, C. M., Lim, S., Wu, C., Feng, J., Eubanks, J. H., & Zhang, L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00451 · Cited by 43 · cited 1×
“In a novel model of extended hippocampal kindling in mice the administration of LEV at 400 mg/kg significantly decreased the number of SRS at 10–12 h post-injection [207].”
BackgroundLevetiracetam exhibits protective properties on rat Schwann cells in vitro
Stettner, M., Dehmel, T., Mausberg, A. K., Köhne, A., Rose, C. R., & Kieseier, B. C. (2011) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2011.00355.x · Cited by 43 · cited 2×
“tive genes and antioxidant response elements [298,299] and has been demonstrated that LEV”
BackgroundZheng, Y. Z., Moussally, J., Cash, S. S., Karnam, H. B., & Cole, A. J. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.12.007 · Cited by 43 · cited 1×
“Similarly, intravenous LEV treatment 30 min after the onset of pilocarpine-induced acute seizures decreased the intensity of the seizures [213].”
BackgroundFalsaperla, R., Mauceri, L., Pavone, P., Barbagallo, M., Vitaliti, G., Ruggieri, M., Pisani, F., & Corsello, G. (2019) · Behavioural Neurology · doi:10.1155/2019/3683548 · Cited by 43 · cited 1×
“In another clinical study with newborns, LEV maintained for one month after the seizures resolved) counteracted the detrimental effect of seizures on the neurodevelopmental outcome, specifically tone and posture [235].”
BackgroundVenkatesan, K., Alix, P., Marquet, A., Doupagne, M., Niespodziany, I., Rogister, B., & Seutin, V. (2012) · Journal of Neuroscience Research · doi:10.1002/jnr.23111 · Cited by 42 · cited 2×
“Since the absence of SV2A presented a normal number of vesicles docked at the active zone in presynaptic terminal [113,115] and the mechanism of exocytosis itself was not affected (no changes were observed in any SV2A KO and SV2A/SV2B DKO hippocampal neurons when examining miniature postsynaptic currents) [109,112,113…”
BackgroundOhno, Y., Ishihara, S., Terada, R., Kikuta, M., Sofue, N., Kawai, Y., Serikawa, T., & Sasa, M. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.09.035 · Cited by 41 · cited 1×
“Moreover, treatment with LEV blocked both the development of a seizure phenotype [130] and increased the hippocampal expression of SV2A [131] in kindled mice and in primary cultures of hippocampal neurons overexpressing SV2A [121].”
BackgroundCorrea-Basurto, J., Cuevas-Hernández, R. I., Phillips-Farfán, B. V., MartÃnez-Archundia, M., Romo-Mancillas, A., RamÃrez-Salinas, G. L., Pérez-González, Ã. A., Trujillo-Ferrara, J., & Mendoza-Torreblanca, J. G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00125 · Cited by 40 · cited 3×
“port the putative LBS observed previously [106] where the residues found by single”
BackgroundSelf-citationLöscher, W., & Hönack, D. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90847-b · Cited by 40 · cited 1×
“Furthermore, LEV was devoid of anticonvulsant effect in the maximal electroshock seizure (MES) and pentylenetetrazol (PTZ) seizure tests [197,198], which are traditionally used to evaluate the effectiveness of AEDs [199], but it markedly suppresses seizures in chronic models such as mice kindled with corneal electrosh…”
BackgroundBragina, L., Fattorini, G., Giovedí, S., Melone, M., Bosco, F., Benfenati, F., & Conti, F. (2012) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2011.00032 · Cited by 39
Mazhar, F., Malhi, S. M., & Sımjee, S. U. (2016) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2016-0034 · Cited by 39 · cited 1×
“) in a kindling model of epilepsy induced by PTZ in rats, the oxidant status in epilepsy was decreased with the use of this AED [24,275].”
BackgroundItoh, K., Taniguchi, R., Matsuo, T., Oguro, A., Vogel, C. F. A., Yamazaki, T., & Ishihara, Y. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134363 · Cited by 39 · cited 1×
“During epileptogenesis, repeated treatment with LEV for 30 days prevented microglial activation, as evidenced by a decrease in morphological changes, phagocytic activity, and cytokine expression [23].”
Inaba, T., Miyamoto, N., Hira, K., Ueno, Y., Yamashiro, K., Watanabe, M., Shimada, Y., Hattori, N., & Urabe, T. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.07.015 · Cited by 39 · cited 1×
“These animals preserved learning and memory capabilities in the Y-maze, spontaneous alternation, and novel object recognition tests [132].”
BackgroundTesting association of rare genetic variants with resistance to three common antiseizure medications
Wolking, S., Moreau, C., Nies, A. T., Schaeffeler, E., McCormack, M., Auce, P., Avberšek, A., Becker, F., Krenn, M., Møller, R. S., et al. (2020) · Epilepsia · doi:10.1111/epi.16467 · Cited by 39 · cited 2×
“investigated the genetic risk of rare variants for drug response to three AEDs (including LEV treatment for at least 1 year) through an analysis of the sequencing, genotyping, variant selection, and annotation of an epileptic cohort derived from the EpiPGX Consortium, to identify genetic biomarkers of epilepsy treatme…”
BackgroundMethodTherapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis
Ohno, Y., & Tokudome, K. (2017) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527316666170404115027 · Cited by 38 · cited 2×
“These data agree with the observations of a great co-expression between SV2A and GABAergic neurons in the amygdala and hippocampus [163,164,166,167].”
BackgroundResultErbaş, O., Oltulu, F., Yılmaz, M., Yavaşoğlu, A., & Taşkıran, D. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.12.016 · Cited by 38 · cited 1×
“) reduces lipoperoxidation, and increases total antioxidant capacity [280,281].”
BackgroundWood, M. D., Sands, Z. A., Vandenplas, C., & Gillard, M. (2018) · Epilepsia · doi:10.1111/epi.14532 · Cited by 37
Beltrán-Sarmiento, E., Arregoitia-Sarabia, C. K., Floriano-Sánchez, E., Sandoval‐Pacheco, R., Galván-Hernández, D. E., Coballase-Urrutía, E., Carmona‐Aparicio, L., Ramos-Reyna, E., Rodríguez‐Silverio, J., & Cárdenas‐Rodríguez, N. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/7954371 · Cited by 37 · cited 1×
“For example, the use of antioxidants can prevent the epileptic process in animal seizure models [267] and in a recent work, we showed that valproic acid, administered by 12 months without interruption acts as an antioxidant in children diagnosed with epilepsy decreasing oxidative markers as malondialdehyde (MDA, a lip…”
BackgroundSelf-citationLevetiracetam for epilepsy: an evidence map of efficacy, safety and economic profiles
Yi, Z., Wen, C., Cai, T., Xu, L., Zhong, X., Zhan, S., & Zhai, S.-D. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s181886 · Cited by 37 · cited 2×
“LEV treatment can promote infections such as pharyngitis, nasopharyngitis, and rhinitis [48,54,55].”
BackgroundSafety and Tolerability of Rapid Administration Undiluted Levetiracetam
Morgan, O., & Medenwald, B. (2019) · Neurocritical Care · doi:10.1007/s12028-019-00708-5 · Cited by 37 · cited 1×
“This probably explains the lack of anticonvulsant activity against acute seizures [198] compared with their potent anticonvulsant action in chronic models, as well as its unique tolerability and safety [202].”
BackgroundRapid administration of undiluted intravenous levetiracetam
Haller, J. T., Bonnin, S. S., & Radosevich, J. J. (2021) · Epilepsia · doi:10.1111/epi.16961 · Cited by 37 · cited 1×
“It is also a preferred agent due to a favorable adverse effect profile [47].”
BackgroundDoelken, M. T., Hammen, T., Bogner, W., Mennecke, A., Stadlbauer, A., Boettcher, U., Doerfler, A., & Stefan, H. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2010.02544.x · Cited by 36 · cited 1×
“The data showed an increase in GABA/creatinine in the occipital lobe in responder patients (those who showed 50–100% seizure reduction), while in non-responders the results were inconclusive [146].”
ResultMohammad, H. M. F., Sami, M. M., Makary, S., Toraih, E. A., Mohamed, A. O., & El-Ghaiesh, S. H. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116588 · Cited by 36 · cited 3×
“The anti-inflammatory effects of LEV also were showed in diabetic mice; treatment with LEV (25 mg/kg) for six weeks reduced the transcription of proinflammatory molecules as NF-κB, TNF-α, IL-6, iNOS and Tumor protein 53 (Tp53), as well as regression of retinal inflammation and improvement in structural organization [2…”
BackgroundVogl, C., Tanifuji, S., Danis, B., Daniels, V., Foerch, P., Wolff, C., Whalley, B. J., Mochida, S., & Stephens, G. J. (2015) · European Journal of Neuroscience · doi:10.1111/ejn.12799 · Cited by 35 · cited 1×
“Interestingly, intracellular LEV administration caused (after 4 to 5 min of exposition) rapid inhibition of the Ca2+ current; this is consistent with a mechanism where LEV may interact directly with HVA Ca2+ channels, causing a reduction in synaptic transmission [19,114].”
Background
Research works printed but not linked: 1
- Christine, A.G., and Devaskar, S.U. (2012). Chapter 61—Central Nervous System Injury and Neuroprotection. Avery’s Diseases of the Newborn (Ninth Edition), W.B. Saunders.
Cited by
Mitochondrial dysfunction and neurological disorders: A narrative review and treatment overview
Alshial, E. E., Abdulghaney, M. I., Wadan, A. S., Abdellatif, M. A., Ramadan, N. E., Suleiman, A. M., Waheed, N., Abdellatif, M., & Mohammed, H. S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122257 · Cited by 98
Neuroinflammation and status epilepticus: a narrative review unraveling a complex interplay
Foiadelli, T., Santangelo, A., Costagliola, G., Costa, E., Scacciati, M., Riva, A., Volpedo, G., Smaldone, M. C., Bonuccelli, A., Clemente, A. M., et al. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1251914 · Cited by 91
de Castro, A. C., Nascimento, F. A., Beltrán‐Corbellini, Á., Toledano, R., García‐Morales, I., Gil‐Nagel, A., & Aledo‐Serrano, Á. (2023) · Seizure · doi:10.1016/j.seizure.2023.03.017 · Cited by 49
The AI Future of Emergency Medicine
Petrella, R. J. (2024) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2024.01.031 · Cited by 43
Current Issues in Pharmacy and Medical Sciences
(2024) · Current Issues in Pharmacy and Medical Sciences · doi:10.12923/j.2084-980x · Cited by 39
Metadata
- Authors
- Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A.
- Affiliations
- Laboratorio de Fisiología, Escuela Militar de Graduados de Sanidad, Ciudad de México 11200, Mexico
- Laboratorio de Neurociencias, Subdirección de Medicina Experimental, Instituto Nacional de Pediatría, Ciudad de México 04530, Mexico
- Laboratorio de Diseño Asistido por Computadora y Síntesis de Fármacos, Facultad de Química, Universidad Autónoma de Querétaro, Centro Universitario, Querétaro 76010, Mexico
- Secretaria de Salud (MX)
- Instituto Politécnico Nacional (MX)
- Laboratorio de Bioquímica Genética, Instituto Nacional de Pediatría, Secretaría de Salud, Ciudad de México 04530, Mexico
- Laboratorio de Inmunoquímica, Hospital Infantil de México Federico Gómez, Secretaría de Salud, Ciudad de México 06720, Mexico
- Departamento de Fisiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 07738, Mexico
- ORCID
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2022-04-13
- Volume
- 15
- Issue
- 4
- Pages
- 475
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC9030752
- OpenAlex
- W4223993843
- Cited by
- 131
- References
- 303
- Citations by year
- 2026: 28 · 2025: 45 · 2024: 37 · 2023: 21
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Keywords
- levetiracetam, antiepileptic drugs, epilepsy, seizure control, SV2A, calcium homeostasis, GABAergic system, AMPA receptors, multi-target drugs, drug repurposing, neuroprotection, anti-inflammatory activity, antioxidant activity, molecular targets
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.